our Premium Content: News alerts, weekly reports and conference planners

GENE:

MAP3K11 (Mitogen-Activated Protein Kinase Kinase Kinase 11)

News alerts, weekly reports and conference planners

Regulation of e-cadherin by mixed lineage kinase (MLK3) mediates cell adhesion in ovarian cancer spheroids. (PubMed, Biochim Biophys Acta Mol Cell Res)

Neither the MLK3-E-cadherin interaction nor the plasma membrane localization of MLK3 is dependent on β-catenin. Collectively, these results indicate a novel function for MLK3 in regulating E-cadherin protein stability, cell adhesion, and ovarian cancer spheroid formation.

1 month ago

Journal

CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CDH1 (Cadherin 1) • MAP3K11 (Mitogen-Activated Protein Kinase Kinase Kinase 11)

3ms

Depletion of LINC01133 from cancer-associated fibroblasts exacerbates the progression of gastric adenocarcinoma. (PubMed, iScience)

In vivo studies confirmed that either overexpression of LINC01133 or inhibition of miR-199a-5p suppresses gastric adenocarcinoma cell growth. In summary, LINC01133 re-activation may serve as a potential therapeutic strategy for inhibiting metastasis in gastric adenocarcinoma.

3 months ago

Journal

KLF4 (Kruppel-like factor 4) • PHLPP1 (PH Domain And Leucine Rich Repeat Protein Phosphatase 1) • CDC42 (Cell Division Cycle 42) • MIR199A (MicroRNA 199a) • LINC01133 (Long Intergenic Non-Protein Coding RNA 1133) • MAP3K11 (Mitogen-Activated Protein Kinase Kinase Kinase 11)

3ms

Protopanaxadiol induces apoptosis through JNK signaling pathway and targeting MLK3 in human melanoma. (PubMed, J Ginseng Res)

Inhibition of JNK with SP600125 reversed PPD-induced apoptosis, indicating that JNK signaling plays a critical role...Our findings revealed that PPD exerts potent anti-melanoma effects by directly targeting MLK3 and activating the MLK3-JNK signaling pathway, leading to apoptosis. These results provide novel insights into the molecular mechanism of PPD and suggest its potential as a therapeutic agent for melanoma treatment.

3 months ago

Journal

MAP3K11 (Mitogen-Activated Protein Kinase Kinase Kinase 11)

SP600125

9ms

Immunosuppressive MAP3K11 as an independent risk factor for progression-free survival promotes prostate cancer metastasis by regulating epithelial-mesenchymal transition. (PubMed, Biochem Biophys Res Commun)

Targeted inhibition of MAP3K11 resists PCa metastasis by limiting EMT onset and mobilizes immune infiltration.

9 months ago

Journal

HRAS (Harvey rat sarcoma viral oncogene homolog) • MAPK1 (Mitogen-activated protein kinase 1) • MAP3K11 (Mitogen-Activated Protein Kinase Kinase Kinase 11) • MAPK11 (Mitogen-Activated Protein Kinase 11)

10ms

Mixed lineage kinase (MLK) controls tumor development and angiogenesis. (PubMed, Angiogenesis)

Additionally, the MLK family of kinases acts through the long noncoding RNA (lncRNA) H19 to control the expression of these pro-angiogenic factors in the endothelium. Collectively, these findings suggest that the MLK-H19 axis coordinates endothelial function, angiogenesis, and tumor growth.

10 months ago

Journal

MAP3K10 (Mitogen-Activated Protein Kinase Kinase Kinase 10) • MMP9 (Matrix metallopeptidase 9) • ADAM8 (ADAM Metallopeptidase Domain 8) • MAP3K11 (Mitogen-Activated Protein Kinase Kinase Kinase 11)

12ms

Prognostic Significance of CDK1 in Ovarian and Cervical Cancers. (PubMed, J Cancer)

Finally, immunohistochemical examination confirmed the expression of some candidate genes in clinical samples. These findings shed light on the molecular causes of OC and CC and will aid the identification of novel targets for future research regarding these cancers, including their diagnosis and treatment.

12 months ago

Journal • Tumor mutational burden

TMB (Tumor Mutational Burden) • CDK2 (Cyclin-dependent kinase 2) • CDK1 (Cyclin-dependent kinase 1) • MIR490 (MicroRNA 490) • MAP3K11 (Mitogen-Activated Protein Kinase Kinase Kinase 11) • UBE2C (Ubiquitin Conjugating Enzyme E2 C)

1year

Exploring MAP3K genes in gastric cancer: biomarkers, tumor microenvironment dynamics, and chemotherapy resistance. (PubMed, Hereditas)

This comprehensive assessment provides valuable insights into the role of MAP3K genes in GC, offering avenues for further research and therapeutic exploration.

1 year ago

Journal

MAP3K10 (Mitogen-Activated Protein Kinase Kinase Kinase 10) • MIR200B (MicroRNA 200b) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1) • MAP3K14 (Mitogen-Activated Protein Kinase Kinase Kinase 14) • MAP3K6 (Mitogen-Activated Protein Kinase Kinase Kinase 6) • MAP3K8 (Mitogen-Activated Protein Kinase Kinase Kinase 8) • MAP3K11 (Mitogen-Activated Protein Kinase Kinase Kinase 11) • MAP3K7 (Mitogen-Activated Protein Kinase Kinase Kinase 7) • MAP3K5 (Mitogen-Activated Protein Kinase Kinase Kinase 5)

1year

Trillin inhibits MAP3K11/NF-κB/COX-2 signaling pathways through upregulation of miR-145-5p in castration-resistant prostate cancer. (PubMed, iScience)

Additionally, Trillin enhances the expression of miR-145-5p, further modulating pathways critical for CRPC progression. These findings suggest that Trillin may offer a promising alternative approach for targeting CRPC, highlighting its potential as a therapeutic agent to improve patient outcomes.

1 year ago

Journal

MAP3K11 (Mitogen-Activated Protein Kinase Kinase Kinase 11) • MIR145 (MicroRNA 145)

1year

Design, Synthesis, and Biochemical Evaluation of Novel MLK3 Inhibitors: A Target Hopping Example. (PubMed, J Med Chem)

In a target hopping example we started with the focal adhesion kinase (FAK) inhibitor PF-431396 (10), which shows off-target activity toward MLK3...Furthermore, we achieved a dramatic shift in selectivity from FAK to MLK3. Here we present a new chemical class of MLK3 inhibitors, including our lead compound 37 with an outstanding IC50 value of <1 nM in a biochemical MLK3 assay while simultaneously exhibiting kinome-wide selectivity.

1 year ago

Journal

MAP3K11 (Mitogen-Activated Protein Kinase Kinase Kinase 11)

benzesulfonate (PF-562271)

over1year

Marine Staurosporine Analogues: Activity and Target Identification in Triple-Negative Breast Cancer. (PubMed, Mar Drugs)

The findings highlighted that compound 4 inhibits breast cancer cell migration, induces apoptosis, arrests the cell cycle, and promotes cellular senescence in both regular and paclitaxel-resistant MDA-MB-231 cells. Additionally, this study identified mitogen-activated protein kinase kinase kinase 11 (MAP3K11) as a target of compound 4, implicating its role in breast tumorigenesis by affecting cell proliferation, migration, and cell cycle progression.

over 1 year ago

Journal

MAP3K11 (Mitogen-Activated Protein Kinase Kinase Kinase 11)

paclitaxel

over1year

Protease activated receptor-1 regulates mixed lineage kinase-3 to drive triple-negative breast cancer tumorigenesis. (PubMed, Cancer Lett)

Our data suggests that activation of the PAR1-MLK3 axis promotes TNBC tumorigenesis. Therefore, combinatorial therapy targeting MLK3 and PAR1 could effectively reduce TNBC tumor burden.

over 1 year ago

Journal

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • MAP3K11 (Mitogen-Activated Protein Kinase Kinase Kinase 11)

over1year

Selective Degradation of MLK3 by a Novel CEP1347-VHL-02 PROTAC Compound Limits the Oncogenic Potential of TNBC. (PubMed, J Med Chem)

Furthermore, we showed that CEP1347-VHL-02 robustly degraded MLK3 and inhibited its oncogenic activity in TNBC, measured as a reduction of clonogenic and migratory potential, cell cycle arrest, and the induction of apoptosis in MDA-MB-468 cells. In conclusion, we present CEP1347-VHL-02 as a novel MLK3 degrader that may be a promising new strategy to target MLK3 in TNBC.

over 1 year ago

Journal

MAP3K11 (Mitogen-Activated Protein Kinase Kinase Kinase 11)